Romidepsin for cutaneous T-cell lymphoma.

@article{Prince2012RomidepsinFC,
  title={Romidepsin for cutaneous T-cell lymphoma.},
  author={H Miles Prince and Michael R. Dickinson},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2012},
  volume={18 13},
  pages={3509-15}
}
Cutaneous T-cell lymphomas (CTCL) are relatively rare lymphomas with an annual incidence of approximately 0.2 to 0.8/100,000 and comprise a variety of clinical entities; mycosis fungoides or its leukemic variant Sezary syndrome account for the majority of cases. Advanced-stage disease is typically treated with bexarotene (a retinoid), interferon, or conventional chemotherapeutic agents, but relapses are inevitable. Histone deacetylase inhibitors, which modify the epigenome, are an attractive… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites

International journal for parasitology. Drugs and drug resistance • 2015
View 4 Excerpts
Highly Influenced

S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86).

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG • 2018

Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth

International journal for parasitology. Drugs and drug resistance • 2017
View 2 Excerpts

Similar Papers

Loading similar papers…